103 related articles for article (PubMed ID: 826997)
1. Parkinsonism: animal analogues of the human disorder.
Duvoisin RC
Res Publ Assoc Res Nerv Ment Dis; 1976; 55():293-303. PubMed ID: 826997
[No Abstract] [Full Text] [Related]
2. Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Poirier LJ; Langelier P; Bédard P; Boucher R; Larochelle L; Parent A; Roberge AG
Adv Neurol; 1974; 5():5-10. PubMed ID: 4216259
[No Abstract] [Full Text] [Related]
3. Stereotaxic lesions and movement disorders in monkeys.
Poirier LJ; Péchadre JC; Larochelle L; Dankova J; Boucher R
Adv Neurol; 1975; 10():5-22. PubMed ID: 807087
[No Abstract] [Full Text] [Related]
4. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Ungerstedt U; Ljungberg T; Steg G
Adv Neurol; 1974; 5():421-6. PubMed ID: 4531217
[No Abstract] [Full Text] [Related]
5. The development of animal models for studies in Parkinson's disease.
Poirier LJ
Contemp Neurol Ser; 1971; 8():83-117. PubMed ID: 5005690
[No Abstract] [Full Text] [Related]
6. Relationship between animal models and clinical parkinsonism.
Marsden CD; Duvoisin RC; Jenner P; Parkes JD; Pycock C; Tarsy D
Adv Neurol; 1975; 9():165-75. PubMed ID: 1146651
[No Abstract] [Full Text] [Related]
7. Experimentally induced parkinsonism.
Poirier LJ; Sourkes TL
Res Publ Assoc Res Nerv Ment Dis; 1972; 50():416-33. PubMed ID: 4403656
[No Abstract] [Full Text] [Related]
8. Actions of levodopa and dopamine in the central nervous system.
Sourkes TL
JAMA; 1971 Dec; 218(13):1909-11. PubMed ID: 4398939
[No Abstract] [Full Text] [Related]
9. The protective role of levodopa in the human substantia nigra.
Rajput AH
Adv Neurol; 2001; 86():327-36. PubMed ID: 11553992
[TBL] [Abstract][Full Text] [Related]
10. [Control of motor activity in relation to monoaminergic mechanisms].
Poirier LJ; Larochelle L; Bédard P; Parent A
Rev Can Biol; 1972; 31():Suppl:175-80. PubMed ID: 4403290
[No Abstract] [Full Text] [Related]
11. Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
Poirier LJ
Confin Neurol; 1974; 36(4-6):223-36. PubMed ID: 4218801
[No Abstract] [Full Text] [Related]
12. Tremorogenisis: effects of reserpine on the substantia nigra.
Pozos RS; Holbrook JR
Exp Neurol; 1971 Sep; 32(3):317-30. PubMed ID: 5110219
[No Abstract] [Full Text] [Related]
13. Is levodopa toxic to human substantia nigra?
Rajput AH; Fenton Me; Birdi S; Macaulay R
Mov Disord; 1997 Sep; 12(5):634-8. PubMed ID: 9380042
[TBL] [Abstract][Full Text] [Related]
14. Experimental tremor following CNS lesions in monkeys.
Dumont M; Lamarre Y
Trans Am Neurol Assoc; 1973; 98():237-9. PubMed ID: 4206372
[No Abstract] [Full Text] [Related]
15. [Modeling parkinsonism (review)].
Atadzhanov M
Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(3):110-9. PubMed ID: 6805182
[No Abstract] [Full Text] [Related]
16. L-DOPA: chemical modifications and biological evaluation.
Brossi A; Pool W; Sheppard H; Burns JJ; Kaiser A; Bigler R; Bartholini G; Pletscher A
Adv Neurol; 1974; 5():291-3. PubMed ID: 4474795
[No Abstract] [Full Text] [Related]
17. The GABA uptake inhibitor beta-alanine reduces pilocarpine-induced tremor and increases extracellular GABA in substantia nigra pars reticulata as measured by microdialysis.
Ishiwari K; Mingote S; Correa M; Trevitt JT; Carlson BB; Salamone JD
J Neurosci Methods; 2004 Dec; 140(1-2):39-46. PubMed ID: 15589332
[TBL] [Abstract][Full Text] [Related]
18. Action of m-tyrosine in experimental models: evidence for possible antiparkinsonian activity.
Ungerstedt U; Fuxe K; Goldstein M; Battista A; Ogawa M; Anagnoste B
Eur J Pharmacol; 1973 Feb; 21(2):230-7. PubMed ID: 4633120
[No Abstract] [Full Text] [Related]
19. Catecholamine-containing grafts in parkinsonism: past and present.
Hoffer BJ; Granholm AC; Stevens JO; Olson L
Clin Res; 1988 Apr; 36(3):189-95. PubMed ID: 3286096
[No Abstract] [Full Text] [Related]
20. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
Paillé V; Henry V; Lescaudron L; Brachet P; Damier P
Mov Disord; 2007 Mar; 22(4):533-9. PubMed ID: 17230470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
